Investigators assessed lifestyle and dietary patterns of more than 2000 men with nonmetastatic prostate cancer using three ...

Patients with mild to moderate sleep apnea had lower mortality rates than those with no sleep apnea and those with severe sleep apnea.

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

PDS Biotechnology (PDSB) announced the publication of clinical results in the Journal of the American Medical Association, JAMA, Oncology. The ...

INAB READ THE FULL INAB RESEARCH REPORT IN8bio, Inc (NASDAQ:INAB) updates survival data for its INB-100 trial in a February ...

Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...

The following is a summary of “Tacrolimus as first line therapy in a U.S. cohort of idiopathic inflammatory myopathies ...